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Abstract
Background: Does the emergence of antimicrobial resistance in Neisseria gonorrhoeae include the erasure of highly
susceptible strains or does it merely involve a stretching of the MIC distribution? If it was the former this would be
important to know as it would increase the probability that the loss of susceptibility is irreversible.
Methods: We conducted a historical analysis based on a literature review of changes of N. gonorrhoeae MIC
distribution over the past 75 years for 3 antimicrobials (benzylpenicillin, ceftriaxone and azithromycin) in five
countries (Denmark, Japan, South Africa, the United Kingdom and the United States).
Results: Changes in MIC distribution were most marked for benzylpenicillin and showed evidence of a right
shifting of MIC distribution that was associated with a reduction/elimination of susceptible strains in all countries. In
the case of ceftriaxone and azithromycin, where only more recent data was available, right shifting was also found
in all countries but the extent of right shifting varied and the evidence for the elimination of susceptible strains was
more mixed.
Conclusions: The finding of right shifting of MIC distribution combined with reduction/elimination of susceptible
strains is of concern since it suggests that this shifting may not be reversible. Since excess antimicrobial
consumption is likely to be responsible for this right shifting, this insight provides additional impetus to promote
antimicrobial stewardship.
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Background
Typically, investigations of antimicrobial resistance (AMR)
in Neisseria gonorrhoeae have focused on the right-hand
tail of the MIC distributions (the subpopulation of N.
gonorrhoeae that acquires AMR) [1–3]. An under investi-
gated topic is what happens to the left-hand tail of the
MIC distribution and whether or not the emergence of
AMR is associated with a right shifting of the entire MIC
distribution including the left-hand tail [4–7]? One previ-
ous ecological analysis of 5 year data from 24 European
countries found that the emergence of gonococcal AMR
was associated with a right shift of the susceptible isolates
[6]. The study did not however characterize the nature of
the right shift. Right shifting could occur via a number of
pathways. Firstly, if a subpopulation of N. gonorrhoeae
acquires AMR this could lead to a bimodal distribution in
the MIC with no/little change in the MIC of the original
‘wild type’ susceptible population (Fig. 1, type A, stage 1)
[6]. In a second stage of this process and following further
selection pressure, the most susceptible gonococci could
become rare. The new ‘wild type’ gonococci would now
constitute a new MIC peak with a right-shifted unimodal
distribution (type A, stage 2). This distribution could then
develop a new subpopulation with even higher MICs
resulting in a new bimodal distribution (Type A, stage 3
etc.). Secondly, the acquisition of AMR could be followed
by a zero-sum stretching of the entire MIC distribution
where the isolates in the left-hand tail are reduced in dir-
ect proportion to the increase of isolates in the right-hand
tail (Fig. 1, type B). Thus in a type A stage 1 shift, the
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increase in gonococcal AMR leads to a wider MIC distribu-
tion. This is then followed, in the second stage, by a reduc-
tion in MIC distribution width as most of the highly
susceptible isolates are lost through evolution. This process
leads to the (close to) elimination of the highly susceptible
isolates in type A (stage 2 and 3) but not B shifts.
An elimination of highly susceptible strains would likely
increase the risk that the loss of susceptibility is irrevers-
ible. This may have important consequences for not only
gonococcal AMR but also that of commensal bacteria.
There is increasing evidence that high antimicrobial
exposure increases the risk of AMR in N. gonorrohoeae as
well as various other Neisseriae and other commensal spe-
cies [6–9]. If excess antimicrobial consumption results in
a type A, stage 2 or 3 trajectory in not only N. gonorrhoeae
but also in these commensal species then this may be a
warning of more wide-ranging adverse effects of antimi-
crobials on our microbiomes and resistomes [10].
In this review we conducted a non-quantitative histor-
ical analysis of how N. gonorrhoeae MIC distributions
for 3 antimicrobials (benzylpenicillin, ceftriaxone and




We selected the five countries, Denmark, Japan, South Af-
rica, the United Kingdom (UK) and the United States
(USA) for the study based on the availability and quality
of data over a long enough time period to answer our
study question. Further selection considerations included
trying to ensure a mix of regions or countries with the
best quality data from early on in the antibiotic era
(Denmark, the UK and the USA). We included Japan since
this country has been noted to be among the first where
AMR has arisen on a number of occasions [2, 11]. Whilst
gonorrhoea transmission disproportionately affects core-
groups in these three high income countries, this is not
the case in South Africa which was chosen to represent a
low to middle income country where most transmission
has been in the general heterosexual population [12].
Search strategy and selection criteria
We conducted a literature review using PUBMED and
Google Scholar to find studies reporting minimum inhibi-
tory concentrations (MIC) or 50% inhibitory concentration
(IC50) distributions from 1940 to the present. MeSH terms
used in the PubMed search (search date: 10/03/2019) were
“Denmark” OR “Japan” OR “South Africa”, OR “United
States” OR “United Kingdom” OR “England” OR “Scotland”
OR “Wales” OR “Ireland”; AND: “gonorrhoea” OR “gonor-
rhea” OR “Neisseria gonorrhoeae”; filters: publication date
from 01/01/1940 until 09/03/2019. Similar search terms
were used for the Google Scholar search (search date: 30/
03/2019). In addition we searched national surveillance
websites for AMR reports: Denmark (www.ssi.dk), Japan
(www.niid.go.jp), South Africa (http://www.nicd.ac.za),
United Kingdom (https://www.gov.uk/government/publica-
tions/gonococcal-resistance-to-antimicrobials-surveillance-
programme-grasp-report) and the United States (https://
Fig. 1 A schematic representation of how N. gonorrhoeae benzylpenicillin MIC distributions could change over time. A type A shift involves in the
first stage, the emergence of a second population of less susceptible isolates (black, long-dashed line). With further selection pressure all the
gonococci move into the higher MIC peak resulting in a right-shifted unimodal distribution (type A, stage 2, black, short-dashed line). This
distribution could then develop a new subpopulation with higher MICs resulting in a new bimodal distribution (Type A, stage 3; grey, long-
dashed line). Alternatively, the decrease in susceptibility results from a shift in the whole population (type B shift, green, short-dashed line)
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www.cdc.gov/std/gisp/default.htm). No studies from the
Republic of Ireland were included.
Inclusion and exclusion criteria
Studies were eligible for inclusion if they reported the
IC50 or MIC distributions for any of the three antibi-
otics and the following was true:
The sampling strategy was not overtly biased. Samples
needed to either be from all or a non-selected group of
patients attending primary care level STI clinics, or based
on national AMR surveillance reports. We excluded all
studies which reported samples where higher AMR was
probable – such as samples which had suspected AMR
sent for confirmatory testing.
We selected the studies reporting MIC distributions
from isolates at the earliest and latest dates from each
country for each antimicrobial. In addition where ever
possible we selected a MIC distribution from the midpoint
between these two time points. All data are presented as
MICs or IC50s. The 1945 benzylpenicillin susceptibility
data from the USA are reported in Oxford units of benzyl-
penicillin per ml. We multiplied this by 1667 to convert
Oxford units to mg of benzylpenicillin [13].
Contemporary EUCAST breakpoints were used to de-
fine AMR: azithromycin resistance, > 0.5 mg/L; ceftriax-
one resistance, > 0.125 mg/L; and benzylpenicillin
resistance, > 1 mg/L (available at: http://www.eucast.org).
Comparisons with EUCAST’s wild type MIC distributions
We also compare the MIC distributions of the three an-
timicrobials with those from the European Committee
on Antimicrobial Susceptibility Testing (EUCAST)
“Antimicrobial wild type distributions of microorgan-
isms” collection [14]. EUCAST has used this data to es-
tablish epidemiological cut-offs (ECOFFs) for ceftriaxone
(0.032mg/L) and azithromycin (1 mg/L), but not for
benzylpenicillin [14, 15]. For these visual comparisons
we compare the EUCAST MIC distributions with the
earliest country distribution.
Statistical analysis
All analyses were performed in STATA 13.0 (StataCorp
LP, College Station, TX, USA). When exact figures were
not reported, IC50/MIC distributions were digitalized
using GetData Graph Digitizer 2.26. For graphical repre-
sentation of MIC distributions, if a study reported the
lowest MIC distribution as less than or equal to a par-
ticular MIC then this MIC value was used.
Results
Historical review
A total of 1203 articles were identified, and 74 articles
reviewed (Fig. 2). Twenty-eight publications were se-
lected to provide the MIC distributions. A summary of
the study characteristics used to provide these distribu-
tions is given in Table 1.
Benzylpenicillin
Denmark
A study by Reyn et al., utilized the same methodology to
assess the IC50s of local isolates from 1944 and 1957, in
parallel [16]. The IC50 distribution in 1944 was normally
distributed with a mode of 0.0144 mg/L. By 1957 the dis-
tribution was bimodal with a first peak that was largely
unchanged from 1944 and a second peak centered
around an IC50 of 0.2 mg/L (Fig. 3).
We could not find papers published after this date that
reported benzylpenicillin IC50 or MIC distributions. A
Danish surveillance report from 2001 however reported
that 40% of 334 isolates in 1999 were benzylpenicillin re-
sistant (MIC > 1mg/L) and that this figure was un-
changed for 5 years [35]. Euro-GASP does not report
MIC distributions per country and thus we were unable
to obtain this data from this source.
Japan
Between 1968 and 2009 the MIC range increased from
0.125–1 to 0.06–64 mg/L [17, 18]. The lowest dilutions
tested were 0.125 in 1968 and 0.06 mg/L in 2009. The
modal MIC increased from 0.5 to 1 mg/L (Fig. 3).
South Africa
The earliest benzylpenicillin MIC distribution was from
1976 and was not dissimilar to the Denmark bimodal dis-
tribution in 1957 with peaks at 0.01 and 0.5mg/L (range
0.006 to 1mg/L) [36]. By 2013, the bimodal MIC distribu-
tion was retained but right shifted with two peaks at 0.25
and 8mg/L [21]. Only 1.6% of isolates in 2013 had a MIC
≤0.06mg/L. Less than half (38.6%) of isolates from 2013
had MICs that overlapped with those from 1976 (Fig. 3).
UK
In 1957 the benzylpenicillin MIC was approximately
bimodally distributed, with peaks at 0.008 (the modal
value) and 0.25 mg/L [23]. By 2001, the range had in-
creased from ≤0.008–0.5 to ≤0.03–8 with a right shifted
modal value of 0.125 mg/L. The lowest dilutions tested
were 0.008 in 1957 and 0.03 mg/L in 2001. The MIC dis-
tribution from the midpoint between these two time
points was from 1994 and was somewhat right shifted
compared to that from 2001. The 2001 data were pro-
vided by the UKs’ national surveillance Gonococcal re-
sistance to antimicrobials surveillance programme
(GRASP, [25]). Unfortunately, GRASP did not report the
benzylpenicillin MIC distribution after 2001.
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USA
Between 1945 and 1987, the benzylpenicillin MIC distri-
bution shifted from 0.0015–0.12 to 0.008–8mg/L [29, 31].
Only 1.5% of the 1987 distribution overlapped with the
1945 distribution. The mode increased from 0.006 to
0.125mg/L. A study from a single laboratory in Boston
that used the same MIC methodology (agar dilution) to
test susceptibility for gonococcal isolates obtained before
1947 with those from 1949, found an increase in the mode
from 0.003 to 0.02 and a right shifting of the distribution
from 0.001–0.005 to 0.003–0.2mg/L (Fig. 3) [30].
EUCAST
The EUCAST wild type penicillin MIC distribution was so
right shifted compared to the distribution from 1945 in the
USA that there is almost no overlap in their distributions
(Fig. 3). The 1945 distribution has a mode of 0.006mg/L
and a range up to 0.012mg/L. The corresponding values
for the EUCAST distribution are 0.125mg/L and 64mg/L.
Azithromycin
Japan
The azithromycin MIC range increased from 0.016–1
mg/L in 1992/93 to 0.015–2 mg/L in 2013 [3, 20]. The
MIC50 increased from 0.125 to 0.25 mg/L over this time
period. In a two-year period, a study from Sendai, Japan,
found a slight right shifting of the MIC distribution be-
tween 2014 and 2015, with the range increasing from
0.03–1 to 0.06–16mg/L (Fig. 4) [11].
South Africa
The prevalence of azithromycin resistance increased
from 5.4 to 68.0% between 1999 and 2013 in the same
clinic in South Africa [21, 22]. This was associated with
a right shift of the entire MIC distribution. The modal
value increased from a MIC of 0.12 to 1 mg/L over this
time period. The percent of isolates with a MIC of ≤0.5
mg/L decreased from 85 to 3% (Fig. 4).
UK
There was a slight increase in the range of azithromycin
MICs between 2001 and 2015 and an increase in modal
MIC from 0.12 to 0.25 mg/L [25, 26]. This was associ-
ated with a decrease in the proportion of isolates with
low MICs (Fig. 4). The midpoint MIC distribution
(2003) revealed a MIC distribution that was intermediate
between those of 2001 and 2015.
USA
Between 1992 and 2017 there was an increase in the
modal azithromycin MIC from 0.06 to 0.25mg/L and an
increase in the MIC range from 0.03–0.5 mg/L to 0.03–
16mg/L. The midpoint MIC distribution was from 2013
and was very similar to that of 2017.
EUCAST
The EUCAST wild type azithromycin MIC distribution
was right shifted compared to the distribution from
1992 in the USA (Fig. 4). The modal MIC and MIC
range for EUCAST were both one dilution higher.
Ceftriaxone
Japan
Between 1995 and 2005 there was a large increase in the
prevalence of isolates with decreased-susceptibility to
ceftriaxone (MIC > 0.125 mg/L) from 0% of 34 isolates
Fig. 2 PRISMA flow chart showing selection of publications from the literature search
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Table 1 Sources and study methodology of benzylpenicillin, ceftriaxone and azithromycin MIC data used in the study
Country/
EUCAST
Antimicrobial Sampling period Study design, testing modality and study reference References
Denmark Benzylpenicillin 1944 & 1957 1944: 90 strains from 90 non-selected patients stored as lyophilized cultures
and tested in 1957 in parallel with and using the same methodology as the
1957 samples as detailed below.
1957: 103 isolates from 96 randomly-selected patients. Benzylpenicillin
susceptibility was assessed using the plate dilution and tablet methods.
The two methods provided highly concordant results. Results are reported
as 50% inhibitory concentrations for the plate dilution method which
provided the most reproducible results. The 50% inhibitory concentrations
were calculated by means of the Karber method.
[16]
Japan Benzylpenicillin 1968 33 gonococcal isolates from 33 consecutive navy personnel attending a
USA navy STI clinic at Yokosuya, Japan, with a diagnosis of urethritis. MICs
were determined via agar dilution following CLSI guidelines.
[17]
2009–2010 83 isolates from 83 individuals with gonococcal male urethritis presenting
to one of 51 facilities in Japan between April 2009 and October 2010 were
sent to a central laboratory for benzylpenicillin MIC testing via agar dilution
in accordance with CLSI guidelines.
[18]
Ceftriaxone 1995–2005 MICs were determined using an agar dilution method with a GC agar base
containing 1% defined growth supplement. Performed on 690 clinical isolates
of N. gonorrhoeae obtained from local STI clinics between 1995 and 2005 in
Kanagwa, Japan.
[19]
2010–2013 MICs were determined using an agar dilution method with a GC agar base
containing 1% defined growth supplement. Performed on 677 clinical isolates
of N. gonorrhoeae obtained from the local STI clinic between January 2010 to
December 2013 in Fukuoka, Japan.
[3]
Azithromycin 1981 to 1984 and
1992 to 1993
27 isolates from 1981 to 1984 and 79 isolates from 1992 to 1993 had their
MICs determined simultaneously via the same methodology via an agar dilution
method with a GC agar base containing 1% defined growth supplement.
[20]
2013 137 isolates from consecutive male and female patients attending STI clinics
in Fukuoka, with ‘genital gonorrhoea’. Susceptibility testing was performed
via agar dilution with GC agar.
[3].
2014/2015 Study performed on 60 isolates from 2014 and 54 isolates from 2015. All
isolates were from males with a confirmed case of gonococcal urethritis.
Azithromycin MICs were determined via the agar dilution method using
GC agar base media supplemented with 1% IsoVitaleX.
[11]
South Africa Benzylpenicillin 1976–77 175 isolates from non-selected men with urethritis presenting to a GUM
clinic in Johannesburg between 1976 and 1977. MICs tested via agar
diffusion using Oxoid DST agar.
[20] [18]
2013 319 isolates from men with urethritis and women with vaginal discharge
syndrome presenting to two GUM clinics in Durban and Pietermaritzburg.
MICs were tested using the agar dilution method. MICs tested via agar
diffusion using Oxoid DST agar.
[21]
Azithromycin 1999 56 isolates from men with urethritis and women with vaginal discharge
syndrome presenting to a single GUM clinic in Durban. MIC testing was
performed with agar diffusion using Oxoid DST agar.
[22]
2013 319 isolates from men with urethritis and women with vaginal discharge
syndrome presenting to two GUM clinics in Durban and Pietermaritzburg.
MICs were tested using the agar dilution method. MICs tested via agar
diffusion using Oxoid DST agar.
[21]
Ceftriaxone 1995 & 1999 In 1995, 61 isolates and in 1999 58 isolates from men with urethritis and
women with vaginal discharge syndrome presenting to a single GUM
clinic in Durban. MIC testing was performed with agar diffusion using
Oxoid DST agar.
[22]
2013 319 isolates from men with urethritis and women with vaginal discharge
syndrome presenting to two GUM clinics in Durban and Pietermaritzburg.
MICs were tested using the agar dilution method. MICs tested via agar
diffusion using Oxoid DST agar.
[21]
UK Benzylpenicillin 1957 Taken from a report produced by the Medical Research Council Working
Party to Examine the Resistance of Gonococci to Benzylpenicillin. Results
for 302 isolates taken in the London area in April to December 1957 are
[23]
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Table 1 Sources and study methodology of benzylpenicillin, ceftriaxone and azithromycin MIC data used in the study (Continued)
Country/
EUCAST
Antimicrobial Sampling period Study design, testing modality and study reference References
provided. All samples were tested centrally via the same agar diffusion technique.
1994 Isolates were from 113 consecutive patients attending the GUM clinic at an
East London GUM clinic over a one-year period. 66% were from men and
3.5% MSM. MICs were determined by agar diffusion.
[24]
2001 In the 2001 Gonococcal resistance to antimicrobials surveillance programme
(GRASP) report, 2542 isolates from 24 participating GUM clinics had their MICs




2003 results are taken from Gonococcal resistance to antimicrobials surveillance
programme (GRASP) Report 2003. In this survey 1977 non-duplicate isolates
had MIC testing performed with agar diffusion using Oxoid DST agar.
Results for 2008 and 2015 are taken from the 2016 Gonococcal resistance to
antimicrobials surveillance programme (GRASP) report [26]. 2008 data: 1276
isolates were tested from 26 GUM clinics in England and Wales. MIC testing
performed with agar diffusion using Oxoid DST agar. No further details provided.
2015 data: 2302 isolates from 1699 unique patients from 23 English GUM clinics
were tested. 87% were men and 72% were MSM. Slight over-representation of
MSM and London residents. MIC testing performed with agar diffusion using
HiMedia DST agar.
[26–28]
Azithromycin 2001 In the 2001 Gonococcal resistance to antimicrobials surveillance programme
(GRASP) report, 2542 isolates from 24 participating GUM clinics had their MICs
ascertained via agar diffusion using Oxoid DST agar. 71% were men and 25%
MSM.
[25]
2003 2003 results are taken from Gonococcal resistance to antimicrobials surveillance
programme (GRASP) Report 2003. In this survey 1977 non-duplicate isolates had
MIC testing performed with agar diffusion using Oxoid DST agar. 72% were from
men and 24% from MSM. 47.1% were from London and 52.9% from outside
London. Azithromycin MIC distributions for the whole country were not provided
but distributions for both London and non-London populations were provided.
These were similar and we use the data for the non-London sample as this was
larger.
[28]
2015 2302 isolates from 1699 unique patients from 23 English GUM clinics were tested.
87% were men and 72% were MSM. Slight over-representation of MSM and
London residents. MIC testing performed with agar diffusion using HiMedia
DST agar
[26]
USA Benzylpenicillin 1945 104 isolates from a non-selected group of female patients with a diagnosis of
gonorrhoea attending a clinic at the University of Texas. MIC were tested via




A study from a single laboratory in Boston that used the same MIC methodology
(agar dilution) to test susceptibility for gonococcal isolates obtained before 1947
(n = 24) with those from 1949 (n = 52). Isolates were from men and women.







The typical annual Gonococcal Isolate Surveillance Project (GISP) methodology is
as follows: Isolates are collected monthly from up to the first 25 men with N.
gonorrhoeae urethritis attending participating STD clinics. Isolates are sent to the
regional laboratories for agar dilution antimicrobial susceptibility testing.
GISP 1987 (benzylpenicillin/ceftriaxone): 6204 isolates from men with urethritis
from 21 clinics presenting between September 1987 and December 1988. MICs
were ascertained at 4 central laboratories using the agar-dilution technique with
GC-II Base medium [31].
GISP 1992 (Azithromycin) Susceptibility testing for azithromycin in GISP began in
1992. GISP 1992 tested 5238 gonococcal isolates [32, 33]
GISP 2013: (ceftriaxone/azithromicin): In GISP 2017 STD clinics affiliated with 27
state or city health departments sent 5093 gonococcal isolates to GISP.
GISP 2017 (ceftriaxone/azithromicin): In GISP 2017 STD clinics affiliated with 27




Azithromycin – 3727 isolates from 10 collections [14]
Benzylpenicillin – 11,826 isolates from 21 collections [14]
Ceftriaxone – 1697 isolates from 11 collections [14]
Abbreviations: GISP - Gonococcal Isolate Surveillance Project; GRASP - Gonococcal resistance to antimicrobials surveillance programme; GUM - GenitoUrinary
Medicine Clinic; MSM -Men who have sex with men; STD -Sexually Transmitted Diseases
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Fig. 3 (See legend on next page.)
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Fig. 3 Distribution of Neisseria gonorrhoeae benzylpenicillin 50% inhibitory concentrations (IC50) distributions for Denmark (i) and minimum
inhibitory concentrations (MIC) distributions for Japan (ii), South Africa (iii), United Kingdom (iv), United States (v), Boston (United States) (vi), and
EUCAST wild type collection (EUCAST WT) (vii). All MIC values are reported in mg/L. Please note that the x-axis between 0.015 and 64 mg/L uses a
doubling scale and below 0.015 mg/L a less than doubling scale to be able to more accurately represent the distribution of more susceptible
strains in the earlier studies
Fig. 4 Distribution of Neisseria gonorrhoeae azithromycin minimum inhibitory concentrations (MIC) distributions for Japan (i), South Africa (ii),
United Kingdom (iii) and the United States (vi) and EUCAST wild type collection (EUCAST WT) (v). All MIC values are reported in mg/L.
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in 1995 to 29.1% of 55 isolates in 2003 and 14.7% of 34
isolates in 2005 [19]. A commensurate increase in cefix-
ime resistance (MIC > 0.125 mg/L) was noted from 2.9%
in 1995 to 47.3% in 2003 and 29.4% in 2005, in Kana-
gawa, Japan [19]. These studies did not report MIC dis-
tributions and thus this could not be graphically
depicted. An unpublished study from the same last au-
thor did however provide MIC distributions from 2001
and 2007 and this demonstrated a large decrease in the
proportion with ceftriaxone in the lowest MIC categories
tested – from 42 to 0.5% for MIC of < 0.03 mg/L (Fig. 5)
[37]. This was associated with commensurate increases
in higher MICs without an increase in the MIC range.
Between 1993/94 and 2013 there was little movement in
the MIC range (≤0.001–0.25 to 0.001–0.12, respectively)
and MIC50–0.016 and 0.015, respectively [3]. Studies
from elsewhere in Japan showed increases in ceftriaxone
and cefixime MICs [2].
South Africa
In 1995, 100% of isolates were in the lowest MIC cat-
egory tested (≤0.007 mg/L). By 1999, this had dropped to
53% [22]. These data were obtained using same method-
ology testing patients attending the same clinics. By
2013 the proportion with MICs of ≤0.007 mg/L had in-
creased again to 77% (Fig. 5) [21].
UK
Between 2003 and 2015, the modal MIC increased from
< 0.002 to 0.008 mg/L and the highest MIC increased
from 0.008 mg/L to 0.3 mg/L [26]. This was associated
with a reduction of isolates in the lowest MIC category
over this time course (76.8 to 4%; Fig. 5). The MIC dis-
tribution for 2008 was not substantially different, though
a slight right shift may be present.
USA
The lowest ceftriaxone concentration tested was 0.001 in
1987 and 0.008 mg/L in 2017 [31, 34]. The distribution
of strains with MIC below 0.008 mg/L can therefore not
be compared between these years. In 2017 0.2% of iso-
lates had MICs ≥0.125 mg/L. This proportion was not
reported in 1987, when the highest MIC reported was
≥0.06, but the GISP reports note that this proportion
has not changed since 2012 [34]. The MIC distribution
in 2013 was similar to that in 2017.
EUCAST
The EUCAST wild type ceftriaxone MIC distribution
was right shifted compared to the distribution from
1987 in the USA (Fig. 5).
Discussion
Our results provide support for both the bimodal (type A)
and the general shift (type B) of MIC distributions over
time. The changes in MIC distribution for ceftriaxone fit
best with a type B shift where the key change in MIC dis-
tribution has been an increase in the prevalence of isolates
with higher MICs and a commensurate decrease but not
elimination of isolates with low MICs. This is most clearly
seen in South Africa where in 1995, 100% of isolates had a
MIC of ≤0.007mg/L, but by 2013 this had been reduced
to 77%. In all three countries, where this could be
assessed, the gonococci with the lowest MIC assessed
were not eradicated over time.
The changes in MIC distribution for benzylpenicillin fit
better with a type A shift. In Boston, for example, the pre-
1947, pre-penicillin isolates are approximately normally
distributed around a MIC of 0.003mg/L. By 1949, a new
sub-population of more resistant isolates has emerged
centering on a MIC of 0.015mg/L (type A, stage 1). By
1987, the USA distribution is approximately normal once
again but now centered around a MIC of 0.125mg/L (type
A, stage 2). Only 1.5% of the 1987 isolates had a MIC of
≤0.012mg/L.
Similarly, in Denmark, the introduction of penicillin is
followed by a new bimodal distribution (type A, stage 1).
The earliest benzylpenicillin MIC distributions from South
Africa (1976) and the UK (1957) are from the penicillin
period and demonstrate bimodal distributions. The later
distributions from these countries are right shifted com-
pared to the earlier period and in the case of South Africa,
exhibit a new bimodal distribution including a new popula-
tion centered on a MIC of 8mg/L (type A, stage 3). The
earliest data from Japan (1968) do not demonstrate a bi-
modal peak but a unimodal distribution centered around a
high MIC of 0.5mg/L. By 2009, similar to South Africa, bi-
modality has emerged as a result of the emergence of a new
population with MICs around 1mg/L (type A, stage 3).
The results for azithromycin are more mixed. South Afri-
ca’s trajectory fits best with type A, stage 2 – the whole
MIC distribution is right shifted. In the UK and USA on
the other hand, the distribution has been stretched to the
right and thus best characterized as type B shifting.
The different trajectories of azithromycin, ceftriaxone
and benzylpenicillin may be due to the different length
of time they were observed for. This hypothesis is com-
patible with the fact that benzylpenicillin which has the
longest follow-up data available exhibited the most
marked changes in MIC distribution. As longer follow-
up data become available for ceftriaxone and azithromy-
cin they may follow a similar trajectory to benzylpenicil-
lin. Formally defining type A and B shifts was beyond
the scope of this analysis. We therefore acknowledge
that our classification of MICs shifts into these types will
remain open to debate until larger datasets are analyzed
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that enables a more formal classification of how MICs
change over time per species. A further considerable
limitation of these analyses is that changes in MIC distri-
butions between studies may reflect differences in ascer-
tainment of susceptibility. An example of this is a
change of supplier of the agar used for susceptibility
testing in the UK’s GRASP in 2015, which was shown to
lead to slight increases in MICs for benzylpenicillin,
ceftriaxone and azithromycin [38]. These limitations
would not however apply to the benzylpenicillin analyses
from Denmark where the isolates from both periods
were tested in parallel using the same methodology. Fur-
ther limitations include the fact that we used the suscep-
tibility data as they were reported and did not assess if
publication or selection biases were present or absent. In
particular we did not assess if changes in the population
Fig. 5 Distribution of Neisseria gonorrhoeae ceftriaxone minimum inhibitory concentrations (MIC) distributions for Japan (i), South Africa (ii),
United Kingdom (iii) and the United States (vi), and EUCAST wild type collection (EUCAST WT) (v). All MIC values are reported in mg/L. (The
lowest ceftriaxone concentration tested was 0.001 in 1987 and 0.008 mg/L in 2017. The distribution of strains with MIC below 0.008 mg/L can
therefore not be compared between these years)
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sampled may have influenced the results. For example, if
subpopulations with higher rates of AMR were more
likely to be included in the later dates this may lead to a
right shifting of MIC distributions. The potential for this
bias is particularly relevant in three of our comparisons:
1. Benzylpenicillin, Japan 1968 versus 2009–2010. In
2009 the samples were form men attending an STI clinic
whereas the samples from 1968 were from navy
personnel who may have been more likely to have ob-
tained their infections from sex workers who have been
shown to have more resistant strains in some studies
[39], 2. Benzylpenicillin, the USA 1945–1949 versus
1987-onwards. The 1940s isolates were from men and
women versus the post 1986 isolates which were all from
men. 3. Azithromycin, the UK, 2001 versus 2015. The
proportion of samples that were from MSM was consid-
erably higher in 2015 which may been responsible for
the right shifting of the MIC distribution [39, 40]. We
were also unable to assess if unreported quality issues
may have affected the accuracy of the data. Other limita-
tions include that our literature search may have missed
published reports, particularly in the early period when
the indexing of articles was suboptimal. A further prob-
lem was that our analysis was limited to three antimicro-
bials in four countries, which limits generalizability.
Finally, our analysis is descriptive and not quantitative.
Our findings from the pre-penicillin period are however
congruent with those from 16 other studies which found
that gonococci in this period were highly susceptible to
penicillin (reviewed in [16]). Likewise, our findings of a bi-
modal penicillin MIC distribution emerging soon after sig-
nificant penicillin exposure are similar to those in multiple
populations around the world [41–43]. There is also evi-
dence from other populations not included in our review
of the emergence of a second bimodal peak in the penicil-
lin MIC distribution in more recent decades [24, 44].
These studies thus provide some support for our finding
that reductions in susceptibility to penicillin, at least in
certain populations, are best characterized by type A shifts
that evolve through up to 3 stages. By the third stage, ben-
zylpenicillin MIC distributions such as those from Japan
and South Africa were so right-shifted that no or very few
isolates have MICs ≤0.03mg/L. Their distribution no lon-
ger overlaps with that of the pre-penicillin population.
How can we explain this?
What mechanisms underpin the decline/extinction of the
lowest MIC populations?
We propose that 3 mechanisms may be relevant: 1) The
zero-sum nature of changes in distributions means that
an increase in the proportion with high MICs necessarily
entails a commensurate decrease in the proportion with
lower MICs; 2) Sustained antimicrobial exposure may
have led to a selective sweep of N. gonorrhoeae whereby
highly sensitive strains were eliminated from the gene
pool/local pangenome; 3) Sustained antimicrobial pres-
sure may have selected for antimicrobial resistance in
commensal bacteria, including commensal Neisseria spp.
If this change is profound enough and there is sufficient
DNA exchange with these commensals then this could
result in the decline or elimination of low MIC strains in
both commensal and pathogenic species.
The first mechanism is able to explain a decline but
not the elimination of low MIC isolates. Support for the
second mechanism comes from studies that have found
associations between the intensity of antimicrobial con-
sumption in the general population and homologous
gonococcal AMR [6, 9]. Furthermore, studies have found
that particular gonococcal genogroups can emerge and
disseminate rapidly displacing other genogroups. For ex-
ample, genogroup 1407, which is strongly associated
with reduced cephalosporin susceptibility, emerged ex-
plosively in Europe around 2007 and rapidly displaced
other more susceptible genogroups [45]. In support of
the third mechanism, recent receipt of ciprofloxacin, cef-
triaxone or cefixime has been established as an inde-
pendent risk factor for homologous AMR in
oropharyngeal commensal Neisseria [8]. The relative
contributions of mechanisms 2 and 3 is likely to vary be-
tween different classes of antimicrobials. For example,
horizontal gene transfer of resistance conferring genes
from commensal Neisseria has been shown to have
played an important role in cephalosporin and macrolide
resistance but not for fluoroquinolone resistance [46].
Conclusions
The major relevance of this study is showing the utility
of longer-term analyses of MIC distribution. Contem-
porary analyses of gonococcal AMR are frequently lim-
ited to the last decade or so [6, 9, 47]. These analyses
will likely miss changes in MIC distribution that occur
slowly over longer periods. In other fields (mainly envir-
onmental conservation) this short-term focus has led to
what has been termed the shifting baseline syndrome,
where in the absence of sufficient knowledge of histor-
ical conditions, members of each new generation accept
the situation in which they are raised as normal [48]. An
important consequence of this syndrome is that it in-
creases an individual’s tolerance of man-made environ-
mental damage.
It is important to remember that the emergence of
AMR in N. gonorrhoeae is not inevitable. Populations in
countries such as the Netherlands with low rates of con-
sumption of macrolides, quinolones and cephalosporins
have correspondingly lower rates of gonococcal AMR
than high consumption countries [6]. The treatment of
choice for gonorrhoea in the rural part of the Northern
Territories, Australia, remains penicillin, because the
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prevalence of penicillin resistance here is still less than
1% [49].
These findings indicate that it is possible to contain
the emergence of gonococcal AMR.
The fact that a unimodal distribution can re-emerge in
stage 2 of a type A shift may compound the shifting base-
line problem. Observers looking at a stage 2 MIC distribu-
tion in isolation may conclude that this represents a wild
type distribution. Indeed, contemporary datasets are fa-
vored in the construction of epidemiological cutoffs
(ECOFFs) for MICs [15]. If one analyzes EUCAST’s ‘Anti-
microbial wild type distributions of microorganisms’
gonococcal dataset with the EUCAST recommended soft-
ware “ECOFFinder”, this generates an ECOFF for benzyl-
penicillin of 8mg/L [15]. Gonococcal isolates with MICs
of over 1 have a high likelihood of non-response to ben-
zylpenicillin therapy [42] which illustrates why it is not
meaningful to try to find penicillin ECOFFs for contem-
porary gonococcal populations that have experienced right
shifting of their MICs. Evaluating ECOFFs from the pre-
penicillin populations would however be more appropri-
ate. Following our historical methodology, the EUCAST
ECOFF MIC distribution would be characterized as hav-
ing undergone a type A, stage 3 shift. Likely because more
recent datasets are favored in the EUCAST dataset, the
older MIC distributions, such as those from 1945 (Fig. 3),
are not included in this distribution.
Further studies could analyze what mechanisms
underpin the elimination of highly susceptible strains,
what the correlates are of populations that have under-
gone a stage 3 as opposed to a stage 1 or 2, type A shift
in penicillin/other antimicrobial AMR? Can this all be
explained by differential antimicrobial exposure? If so
are there thresholds of consumption that populations
should aim to not exceed [10]? Which gonococcal geno-
types/genogroups have been driven extinct in popula-
tions with stage 2 and 3 shifts? Is this mirrored by a
similar extinction in susceptible strains in commensal
species? Finally, it may be useful to investigate if this
process has played a role in the reduction in diversity of
the gut microbiome in Western populations [50, 51].
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